Literature DB >> 16107837

Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Jordan J Feld1, Jay H Hoofnagle.   

Abstract

Since the identification of the hepatitis C virus, great strides have been made in the development of an antiviral therapy. As a crucial mediator of the innate antiviral immune response, interferon-alpha (IFN-alpha) was a natural choice for treatment. Whereas treatment with IFN-alpha alone achieved only modest success, the addition of the broad-spectrum antiviral agent ribavirin greatly improved responses. However, half of the infected individuals with chronic disease do not achieve sustained clearance of hepatitis C virus. To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107837     DOI: 10.1038/nature04082

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  323 in total

1.  Review.

Authors:  Gloria Taliani; Elisa Biliotti
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-08

2.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 3.  Ion channels as antivirus targets.

Authors:  Xin Liang; Zhi-Yuan Li
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

Review 4.  A perspective on modelling hepatitis C virus infection.

Authors:  J Guedj; L Rong; H Dahari; A S Perelson
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

Review 5.  Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.

Authors:  Paul Y Kwo; Maaz B Badshah
Journal:  Curr Gastroenterol Rep       Date:  2015-10

Review 6.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

7.  Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.

Authors:  Armanda Casrouge; Jérémie Decalf; Mina Ahloulay; Cyril Lababidi; Hala Mansour; Anaïs Vallet-Pichard; Vincent Mallet; Estelle Mottez; James Mapes; Arnaud Fontanet; Stanislas Pol; Matthew L Albert
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

8.  Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.

Authors:  Gamal Badr; Nathalie Bédard; Mohamed S Abdel-Hakeem; Lydie Trautmann; Bernard Willems; Jean-Pierre Villeneuve; Elias K Haddad; Rafick P Sékaly; Julie Bruneau; Naglaa H Shoukry
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 9.  Management strategies for hepatitis C virus infection in children.

Authors:  Suzanne M Davison; Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  Novel function of CD81 in controlling hepatitis C virus replication.

Authors:  Yong-Yuan Zhang; Bai-Hua Zhang; Koji Ishii; T Jake Liang
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.